In re Celebrex Antitrust Litig., No. 14-00361 (E.D. Va.)

In re Celebrex Antitrust Litig., No. 14-00361 (E.D. Va.), Faruqi & Faruqi representing a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer’s blockbuster anti-inflammatory drug, Celebrex, alleging that Pfizer procured a patent by fraud and then filed patent litigation against generic drugmakers to delay their entry into the market with less-expensive generic versions of Celebrex, which had annual sales of over $1 billion during the relevant time. (settled for $94 million)